You are here

P&T December 2017


But Drug Companies and Some Patient Groups Want Changes
State “Right to Try” laws, which allow terminally ill patients to seek investigational treatments under certain circumstances, have created pressure for Congress to follow up with a federal law. Though facing opposition from patient advocates and the drug industry, a bill passed by the Senate is now making its way to the House.
Nanopharmaceuticals, many of which are already in clinical use, can impart pharmacokinetic, efficacy, safety, and targeting benefits compared with conventional drug formulations. We present FDA-approved and investigational nanodrugs, their structures and benefits, and the many challenges they face in development.
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a severe reduction in peripheral blood platelet count. This article reviews the pathophysiology of ITP and summarizes the updates in ITP management and treatment.
Pipeline Plus
Despite the many medications already available, patients with heart failure often have disease exacerbations, reduced quality of life, and increased mortality, highlighting the need for new treatment approaches. We explore drugs currently in development.
Hospital-acquired and ventilator-associated pneumonia continue to represent the most common nosocomial-associated infections. The authors consider the recent IDSA guidelines for diagnosis and management, and outline the key points of change.
Season’s Greetings


Prescription: Washington
Over-the-counter products in line for user fee program
Medication Errors
Epinephrine for anaphylaxis: Autoinjector or 1-mg vial or ampoule?
New Drugs/Drug News
Approvals, new indications, regulatory activities, and more
Secnidazole (Solosec) for the one-dose treatment of bacterial vaginosis; triamcinolone acetonide extended-release injection (Zilretta) for osteoarthritis knee pain; and insulin aspart injection (Fiasp), a rapidacting human insulin analogue for glycemic control in diabetes mellitus
Drug Forecast
Bezlotoxumab (Zinplava) to prevent the recurrence of Clostridium difficile infection